• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Citius Pharmaceuticals Inc (NQ: CTXR )

    0.5163 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 8,629
    Open 0.5163
    Bid (Size) 0.5163 (14)
    Ask (Size) 0.5885 (5)
    Prev. Close 0.5163
    Today's Range 0.5163 - 0.5163
    52wk Range 0.4800 - 1.070
    Shares Outstanding 145,979,429
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024
    CTXR stock results show that Citius Pharma met analyst estimates for earnings per share the third quarter of 2024. 
    Via InvestorPlace
    Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection
    Citius Pharmaceuticals receives FDA approval for Lymphir, the first therapy targeting the IL-2 receptor in relapsed or refractory cutaneous T-cell lymphoma. U.S. market launch planned within five... 
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    -36.16%
    -36.16%
    1 Month
    -24.07%
    -24.07%
    3 Month
    -17.01%
    -17.01%
    6 Month
    -37.35%
    -37.35%
    1 Year
    -20.69%
    -20.69%

    More News

    Read More
    Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology
    Via News Direct
    Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products
    Via News Direct
    This Pharma Company Is Preparing To Launch Its Lead Candidate
    Via News Direct
    Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
    Via Newsfile
    Exposures Product Safety
    Analysts Hunt for Undervalued Biotech Stocks
    Via Newsfile
    Topics Economy Initial Public Offering
    Exposures Interest Rates Securities Market
    Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval
    Via AB Newswire
    Bloodstream Infections - From Threats to Solutions
    Via Newsfile
    Topics Death
    Exposures Death
    Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024
    Via AB Newswire
    Exposures Product Safety
    Biopharma Stocks Transformative Innovation for the Future of Health
    Via Newsfile
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Citius Pharma's 'Antibiotic Lock' Effective In Patients With Catheter-Associated Bloodstream Infections
    Via Benzinga
    Yogi Tea Recalls: Yogi Brand Recalls 900,000 Tea Bags for Pesticide Residue
    Via InvestorPlace
    Topics Product Recall
    Exposures Legal Product Safety
    VFS Stock Alert: VinFast Plunges on NHTSA Probe
    Via InvestorPlace
    Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Featured in Coverage of the EF Hutton Annual Global Conference
    Via Investor Brand Network
    Exposures Product Safety
    CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024
    Via InvestorPlace
    Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment
    Via News Direct
    Topics Death
    Exposures Death
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    Sidoti Events, LLC’s Virtual November Micro-Cap Conference
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
    Via Benzinga
    Why Citius Pharmaceuticals Stock Is Plunging Today?
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.